SCHEMBL15034041

SCHEMBL15034041

COc1cccc(C(=O)N2CCN(C(=O)c3ncn(-c4cccc(Cl)c4)n3)C(C)(C)C2)n1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.39
EPHX2 P34913 1/20 0.39
CFTR P13569 1/20 0.38
MAPT P10636 4/20 0.38
POLB P06746 2/20 0.38
KCNK3 O14649 1/20 0.38
KCNK9 Q9NPC2 1/20 0.38
MGLL Q99685 3/20 0.37
SLC6A7 Q99884 1/20 0.37
CCKAR P32238 2/20 0.37
HRH3 Q9Y5N1 1/20 0.36
NOTUM Q6P988 1/20 0.36
NPC1 O15118 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15019975 0.97 GRM5 (0.41) GRM5EPHX2CFTRMAPTPOLB
SCHEMBL15034042 0.92 GRM5 (0.40) GRM5CFTRMAPTPOLBKCNK3
SCHEMBL15034086 0.92 KCNK3 (0.41) GRM5CFTRMAPTPOLBKCNK3
SCHEMBL15019969 0.92 CFTR (0.40) EPHX2CFTRMAPTPOLBKCNK3
SCHEMBL15034128 0.91 CFTR (0.42) CFTRMAPTPOLBKCNK3KCNK9
SCHEMBL15034045 0.91 KCNK3 (0.40) GRM5CFTRMAPTPOLBKCNK3
SCHEMBL15034026 0.91 CFTR (0.38) GRM5CFTRMAPTKCNK3KCNK9
SCHEMBL15034032 0.90 GRM5 (0.39) GRM5CFTRMAPTPOLBMGLL
SCHEMBL15019498 0.90 GRM5 (0.39) GRM5CFTRMAPTPOLBMGLL
SCHEMBL15034340 0.90 EPHX2 (0.38) GRM5EPHX2MAPTPOLBKCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158042-A1 NOVEL COMPOUNDS GRM5, GRIK5, GRM1 GRM5 1/4885EPHX2 2908/4885CFTR 3753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.